Literature DB >> 546785

Synergistic protection against experimental cholera by immunization with cholera toxoid and vaccine.

J W Peterson.   

Abstract

Rabbits were immunized with two parenteral injections of Wellcome toxoid PX389A, Wyeth toxoid 20101, or Merck bivalent vaccine. Other groups of rabbits were immunized with combinations of the Merck vaccine and each of the two toxoids. Antitoxin responses were monitored in each group of rabbits before livecell challenge of each animal by the ligated intestinal loop assay. Inaba and Ogawa strains of Vibrio cholerae were used for challenge experiments. Basically, the data indicate that the toxoids were equivalent in antigenic potency and antitoxin responses were unaffected by combination of the toxoids with the whole-cell vaccine. The 50 microgram doses of each toxoid as well as the 4 X 10(9) cells of the bivalent vaccine provided the same magnitude of protection against live-cell challenge with either Inaba or Ogawa vibrios. Immunization with either toxoid in combination with the bivalent vaccine resulted in a synergistic protective response against live-cell challenge of intestinal loops with V. cholerae. Synergistic protection was observed when toxoid and vaccine were administered together by the oral and parenteral routes. Maximum protection was obtained when rabbits were immunized with the combined toxoid-whole-cell vaccine administered by both oral and parenteral routes.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 546785      PMCID: PMC414648          DOI: 10.1128/iai.26.2.528-533.1979

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  12 in total

1.  An evaluation of intestinal fluids in the pathogenesis of cholera.

Authors:  R FRETER; H L SMITH; F J SWEENEY
Journal:  J Infect Dis       Date:  1961 Jul-Aug       Impact factor: 5.226

2.  Evidence in intact cells for an involvement of GTP in the activation of adenylate cyclase.

Authors:  G S Johnson; V R Mukku
Journal:  J Biol Chem       Date:  1979-01-10       Impact factor: 5.157

3.  Distribution of cholera organisms in experimental Vibrio cholerae infections: proposed mechanisms of pathogenesis and antibacterial immunity.

Authors:  G D Schrank; W F Verwey
Journal:  Infect Immun       Date:  1976-01       Impact factor: 3.441

4.  Synergistic protective effect in rabbits of immunization with Vibrio cholerae lipopolysaccharide and toxin/toxoid.

Authors:  A M Svennerholm; J Holmgren
Journal:  Infect Immun       Date:  1976-03       Impact factor: 3.441

5.  Deactivation of cholera toxin by a sialidase-resistant monosialosylganglioside.

Authors:  C A King; W E Van Heyningen
Journal:  J Infect Dis       Date:  1973-06       Impact factor: 5.226

6.  A controlled field trial of the effectiveness of cholera and cholera El Tor vaccines in the Philippines.

Authors:  J C Azurin; A Cruz; T P Pesigan; M Alvero; T Camena; R Suplido; L Ledesma; C Z Gomez
Journal:  Bull World Health Organ       Date:  1967       Impact factor: 9.408

7.  Antigenicity of cholera toxoid in humans.

Authors:  R Germanier; E Fürer; S Varallyay; T M Inderbitzin
Journal:  J Infect Dis       Date:  1977-04       Impact factor: 5.226

8.  Vibrio cholerae adherence and colonization in experimental cholera: electron microscopic studies.

Authors:  E T Nelson; J D Clements; R A Finkelstein
Journal:  Infect Immun       Date:  1976-08       Impact factor: 3.441

9.  Mechanism of action of Vibrio cholerae enterotoxin. Effects on adenylate cyclase of toad and rat erythrocyte plasma membranes.

Authors:  V Bennett; P Cuatrecasas
Journal:  J Membr Biol       Date:  1975-06-03       Impact factor: 1.843

10.  In vitro detection of antibody to cholera enterotoxin in cholera patients and laboratory animals.

Authors:  R A Finkelstein; J W Peterson
Journal:  Infect Immun       Date:  1970-01       Impact factor: 3.441

View more
  13 in total

1.  Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin.

Authors:  R K Gupta; S C Szu; R A Finkelstein; J B Robbins
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

2.  Interventions for the control of diarrhoeal diseases among young children: rotavirus and cholera immunization.

Authors:  I de Zoysa; R G Feachem
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

3.  Protection against experimental cholera by oral or parenteral immunization.

Authors:  J W Peterson
Journal:  Infect Immun       Date:  1979-11       Impact factor: 3.441

Review 4.  Cholera.

Authors:  J B Kaper; J G Morris; M M Levine
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

5.  Improved protection against cholera in adult rabbits with a combined flagellar-toxoid vaccine.

Authors:  I G Resnick; C W Ford; G M Shackleford; L J Berry
Journal:  Infect Immun       Date:  1980-11       Impact factor: 3.441

6.  The utility of human challenge studies in vaccine development: lessons learned from cholera.

Authors:  Debbie-Ann T Shirley; Monica A McArthur
Journal:  Vaccine (Auckl)       Date:  2011-10

7.  Successful colonization and immunization of adult rabbits by oral inoculation with Vibrio cholerae O1.

Authors:  W C Cray; E Tokunaga; N F Pierce
Journal:  Infect Immun       Date:  1983-08       Impact factor: 3.441

8.  Oral immunization of dogs with purified cholera toxin, crude cholera toxin, or B subunit: evidence for synergistic protection by antitoxic and antibacterial mechanisms.

Authors:  N F Pierce; W C Cray; J B Sacci
Journal:  Infect Immun       Date:  1982-08       Impact factor: 3.441

9.  Pathogenesis of experimental salmonellosis: inhibition of protein synthesis by cytotoxin.

Authors:  F C Koo; J W Peterson; C W Houston; N C Molina
Journal:  Infect Immun       Date:  1984-01       Impact factor: 3.441

10.  Procholeragenoid: a safe and effective antigen for oral immunization against experimental cholera.

Authors:  N F Pierce; W C Cray; J B Sacci; J P Craig; R Germanier; E Fürer
Journal:  Infect Immun       Date:  1983-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.